Lead Product(s): TRC253
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: TRACON Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 24, 2020
The announcement came in the sense of Janssen Pharma's decision not to exercise their option to re-acquire TRC253's global rights after a analysis of the data in Phase 2.